Circumvention of glucocorticoid resistance in childhood leukemia.

[1]  J. Cawley,et al.  Glucocorticoid binding and cytolethal responsiveness of hairy-cell and chronic lymphocytic leukaemia. , 2008, Clinical and laboratory haematology.

[2]  J. Styczyński,et al.  Ex vivo modulation of response to prednisolone in childhood acute lymphoblastic leukaemia , 2006, British journal of haematology.

[3]  Y. Gedik,et al.  COMPARISION OF THE APOPTOTIC EFFECTS ON LYMPHOBLASTS AND ON INCREASE OF MYELOID LINEAGE CELLS OF A SHORT-TIME, HIGH-DOSE METHYLPREDNISOLONE AND THE CONVENTIONAL-DOSE PREDNISOLONE TREATMENTS IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA , 2006, Pediatric hematology and oncology.

[4]  J. Styczyński,et al.  Cytotoxicity of cortivazol in childhood acute lymphoblastic leukemia. , 2005, Anticancer research.

[5]  W. Bleyer,et al.  Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983–1995 , 2000, Leukemia.

[6]  J. Harbott,et al.  Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995 , 2000, Leukemia.

[7]  F. Mandelli,et al.  Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Acute Lymphoblastic Leukemia Studies, 1982–1995 , 2000, Leukemia.

[8]  G. Janka‐Schaub,et al.  Co-operative study group for childhood acute lymphoblastic leukemia (COALL): long-term follow-up of trials 82, 85, 89 and 92 , 2000, Leukemia.

[9]  A. Berg,et al.  Long-term follow-up of Dutch Childhood Leukemia Study Group (DCLSG) protocols for children with acute lymphoblastic leukemia, 1984–1991 , 2000, Leukemia.

[10]  R. Pieters,et al.  In Vitro Cellular Drug Resistance and Prognosis in Newly Diagnosed Childhood Acute Lymphoblastic Leukemia , 1997 .

[11]  T. Hongo,et al.  In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia. , 1997, Blood.

[12]  D. Campana,et al.  Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Pieters,et al.  Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. , 1996, Medical and pediatric oncology.

[14]  W. Kamps,et al.  High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia. Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  P. Gaynon,et al.  The Use of Glucocorticoids in Acute Lymphoblastic Leukemia of Childhood Molecular, Cellular, and Clinical Considerations , 1995, Journal of pediatric hematology/oncology.

[16]  R. Pieters,et al.  Mononuclear cells contaminating acute lymphoblastic leukaemic samples tested for cellular drug resistance using the methyl-thiazol-tetrazolium assay. , 1994, British Journal of Cancer.

[17]  R. Pieters,et al.  Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia , 1991, The Lancet.

[18]  E. Thompson,et al.  Cortivazol mediated induction of glucocorticoid receptor messenger ribonucleic acid in wild-type and dexamethasone-resistant human leukemic (CEM) cells , 1991, The Journal of Steroid Biochemistry and Molecular Biology.

[19]  F. Zeelen.  Determination of the affinity of a steroid for its receptor is not sufficient to measure its intrinsic hormonal activity , 1990, Steroids.

[20]  H. Hoogsteden,et al.  [1949-1989: glucocorticoids, their receptors and variable clinical response]. , 1989, Nederlandsch tijdschrift voor geneeskunde.

[21]  E. Thompson,et al.  Interactions of the phenylpyrazolo steroid cortivazol with glucocorticoid receptors in steroid-sensitive and -resistant human leukemic cells. , 1989, Cancer research.

[22]  R. Pieters,et al.  Adaptation of the rapid automated tetrazolium dye based (MTT) assay for chemosensitivity testing in childhood leukemia. , 1988, Cancer letters.

[23]  J. Ritter,et al.  Die Corticosteroid-abhängige Dezimierung der Leukämiezellzahl im Blut als Prognosefaktor bei der akuten lymphoblastischen Leukämie im Kindesalter (Therapiestudie ALL-BFM 83) , 1987 .

[24]  J. Schlechte,et al.  Use of [3H]cortivazol to characterize glucocorticoid receptors in a dexamethasone-resistant human leukemic cell line. , 1987, The Journal of clinical endocrinology and metabolism.

[25]  M. Ponec,et al.  Glucocorticoids: binding affinity and lipophilicity. , 1986, Journal of pharmaceutical sciences.

[26]  W. Stigelman,et al.  Goodman and Gilman's the Pharmacological Basis of Therapeutics , 1986 .

[27]  M. Izawa,et al.  Stability of receptor complexes in the rat liver bound to glucocorticoids of different biopotencies. , 1984, Endocrinologia japonica.

[28]  J. Harmon,et al.  Non-glucocorticoid receptor-mediated effects of the potent glucocorticoid deacylcortivazol. , 1982, Cancer research.

[29]  F. Valeriote,et al.  Synergistic interaction of anticancer agents: a cellular perspective. , 1975, Cancer chemotherapy reports.

[30]  G. Hiçsönmez.  The effect of steroid on myeloid leukemic cells: the potential of short-course high-dose methylprednisolone treatment in inducing differentiation, apoptosis and in stimulating myelopoiesis. , 2006, Leukemia research.

[31]  J. Harbott,et al.  Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster. , 2000, Leukemia.

[32]  R. Pieters,et al.  Clinical relevance of in vitro drug resistance testing in childhood acute lymphoblastic leukemia: the state of the art. , 1994, Medical and pediatric oncology.

[33]  T. Mcelwain,et al.  High-dose methylprednisolone sodium succinate as a single agent in relapsed childhood acute lymphoblastic leukaemia. , 1992, Medical and pediatric oncology.

[34]  J. Shuster,et al.  Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia. , 1991, Medical and pediatric oncology.

[35]  F. Balis,et al.  Central nervous system pharmacology of antileukemic drugs. , 1989, The American journal of pediatric hematology/oncology.

[36]  V. Sondak,et al.  In vitro testing of chemotherapeutic combinations in a rapid thymidine incorporation assay. , 1988, International journal of cell cloning.

[37]  Erik Knol,et al.  Potentiation of glucocorticoid-induced lysis in refractory and resistant leukemia cells by inhibitors of ADP-ribosylation. , 1988, Leukemia research.

[38]  F. Berthold,et al.  [Corticosteroid-dependent reduction of leukocyte count in blood as a prognostic factor in acute lymphoblastic leukemia in childhood (therapy study ALL-BFM 83)]. , 1987, Klinische Padiatrie.

[39]  L. Goodman,et al.  The Pharmacological Basis of Therapeutics , 1976 .